TY  - JOUR

T1  - Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

JO  - Blood

UR  - https://doi.org/10.1182/blood-2019-121870

PY  - 2019/11/13

AU  - Vadakekolathu J

AU  - Minden MD

AU  - Hood T

AU  - Church SE

AU  - Reeder S

AU  - Altmann H

AU  - Sullivan AH

AU  - Viboch EJ

AU  - Patel T

AU  - Ibrahimova N

AU  - Warren SE et al

ED  - 

DO  - DOI: 10.1182/blood-2019-121870

PB  - American Society of Hematology

VL  - 134

IS  - Supplement_1

SP  - 460

EP  - 460

Y2  - 2026/02/25

ER  -